Unjoni Ewropea - Litwanjan - EMA (European Medicines Agency)

roche registration limited - emicizumab - hemofilija a - antihemoraginiai - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra gali būti naudojami visose amžiaus grupėse.

Litwanja - Litwanjan - SMCA (Valstybinė vaistų kontrolės tarnyba)

leo pharma a/s - kalcipotriolis/betametazonas - odos putos - 50 µg/0,5 mg/g - calcipotriol, combinations

Litwanja - Litwanjan - SMCA (Valstybinė vaistų kontrolės tarnyba)

stada arzneimittel ag - tamsulozino hidrochloridas - modifikuoto atpalaidavimo kietosios kapsulės - 0,4 mg - tamsulosin

Litwanja - Litwanjan - SMCA (Valstybinė vaistų kontrolės tarnyba)

boehringer ingelheim international gmbh - dipiridamolis/acetilsalicilo rūgštis - modifikuoto atpalaidavimo kietosios kapsulės - 200 mg/25 mg - combinations

Litwanja - Litwanjan - SMCA (Valstybinė vaistų kontrolės tarnyba)

bausch health ireland limited - oktenidino dihidrochloridas/fenoksietanolis - odos purškalas (tirpalas) - 1 mg/20 mg/ml - octenidine, combinations

Litwanja - Litwanjan - SMCA (Valstybinė vaistų kontrolės tarnyba)

pfizer europe ma eeig - dalteparino natrio druska - injekcinis tirpalas - 10000 anti-xa tv/ml; 5000 anti-xa tv/0,2 ml; 2500 anti-xa tv/0,2 ml; 18000 anti-xa tv/0,72 ml; 15000 anti-xa tv/0,6 ml; 12500 anti-xa tv/0,5 ml; 10000 anti-xa tv/0,4 ml; 7500 anti-xa tv/0,3 ml; 100 - dalteparin

Unjoni Ewropea - Litwanjan - EMA (European Medicines Agency)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - imuninės serumai ir imunoglobulinai, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Unjoni Ewropea - Litwanjan - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - dantų atmetimas - imunosupresantai - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Unjoni Ewropea - Litwanjan - EMA (European Medicines Agency)

h. lundbeck a/s - eptinezumab - migrenos sutrikimai - analgetikai - vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

Unjoni Ewropea - Litwanjan - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - ertapenemo natrio druska - bakterinė infekcija - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 ir 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antibakterinių veiksnių.